JP7867482B2 - イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用 - Google Patents

イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用

Info

Publication number
JP7867482B2
JP7867482B2 JP2023502881A JP2023502881A JP7867482B2 JP 7867482 B2 JP7867482 B2 JP 7867482B2 JP 2023502881 A JP2023502881 A JP 2023502881A JP 2023502881 A JP2023502881 A JP 2023502881A JP 7867482 B2 JP7867482 B2 JP 7867482B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
formula
acceptable salt
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023502881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533855A5 (enExample
JP2023533855A (ja
Inventor
アックスマン、アリソン
エイチ． ドリューリー、デイビッド
ケイ． ジャヤウィックリーム、チャンナ
セレンスキー、キャロリン
エイチ． スミス、スーザン
ポール トランプ、ライアン
ウェルズ、カロウ
ウィルソン、ティモシー
ジャン、カンユ
ズアーチャー、ウィリアム
Original Assignee
ダーマヴァント サイエンシーズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダーマヴァント サイエンシーズ ゲーエムベーハー filed Critical ダーマヴァント サイエンシーズ ゲーエムベーハー
Publication of JP2023533855A publication Critical patent/JP2023533855A/ja
Publication of JP2023533855A5 publication Critical patent/JP2023533855A5/ja
Application granted granted Critical
Publication of JP7867482B2 publication Critical patent/JP7867482B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
JP2023502881A 2020-07-16 2021-05-27 イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用 Active JP7867482B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063052574P 2020-07-16 2020-07-16
US202063052561P 2020-07-16 2020-07-16
US63/052,574 2020-07-16
US63/052,561 2020-07-16
PCT/US2021/034599 WO2022015423A1 (en) 2020-07-16 2021-05-27 ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE

Publications (3)

Publication Number Publication Date
JP2023533855A JP2023533855A (ja) 2023-08-04
JP2023533855A5 JP2023533855A5 (enExample) 2025-09-12
JP7867482B2 true JP7867482B2 (ja) 2026-05-29

Family

ID=79293345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502881A Active JP7867482B2 (ja) 2020-07-16 2021-05-27 イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用

Country Status (10)

Country Link
US (5) US11267788B2 (enExample)
EP (2) EP4786453A2 (enExample)
JP (1) JP7867482B2 (enExample)
KR (1) KR20230041021A (enExample)
CN (1) CN116157387B (enExample)
AU (1) AU2021308209A1 (enExample)
CA (1) CA3185793A1 (enExample)
IL (1) IL299756A (enExample)
MX (1) MX2023000263A (enExample)
WO (1) WO2022015423A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11267788B2 (en) 2020-07-16 2022-03-08 Dermavant Sciences GmbH Isoquinoline compounds and their use in treating AhR imbalance
WO2024020170A1 (en) * 2022-07-21 2024-01-25 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof
US20260069585A1 (en) * 2022-08-30 2026-03-12 Dermavant Sciences GmbH ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
WO2024152993A1 (zh) * 2023-01-17 2024-07-25 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
CN117447402A (zh) * 2023-10-18 2024-01-26 德明药泰生物技术（深圳）有限公司 芳香烃受体调节剂类化合物及其制备方法和应用
CN117229208B (zh) * 2023-11-13 2024-02-23 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
WO2026083733A1 (ja) * 2024-10-18 2026-04-23 株式会社ヤクルト本社 試験方法、ゲル状組成物、及び試験装置
WO2026096218A1 (en) * 2024-10-18 2026-05-07 Dermavant Sciences GmbH Pharmaceutical compositions for respiratory administration and methods of treating inflammatory diseases of the lungs
WO2026085237A1 (en) * 2024-10-18 2026-04-23 Dermavant Sciences GmbH Process for preparing 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
JP2005516941A (ja) 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド カルコン誘導体及び疾患を治療するためのそれらの使用
WO2011156626A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
WO2019158453A1 (de) 2018-02-13 2019-08-22 Merck Patent Gmbh Metallkomplexe
JP2020515604A (ja) 2017-03-29 2020-05-28 メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ 金属錯体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504791A (ja) 1991-04-10 1994-06-02 オクタマー，インコーポレイティド レトロウィルス複製の阻害のための方法
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
WO1999018077A1 (en) * 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
DE60233414D1 (de) 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
EP1704856A4 (en) 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
WO2006058201A2 (en) 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
JP5439127B2 (ja) 2009-11-13 2014-03-12 株式会社さいわいメディカル 乾癬又はアトピー性皮膚炎治療剤
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
GB201304041D0 (en) 2013-03-06 2013-04-17 Water Jel Europ Llp Treatment and prophylaxis of radiation dermatitis
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
TWI828664B (zh) 2018-03-19 2024-01-11 愛爾蘭商Ｕｄｃ愛爾蘭責任有限公司 金屬錯合物
US11267788B2 (en) 2020-07-16 2022-03-08 Dermavant Sciences GmbH Isoquinoline compounds and their use in treating AhR imbalance
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN116947799B (zh) * 2023-03-08 2024-05-03 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
JP2005516941A (ja) 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド カルコン誘導体及び疾患を治療するためのそれらの使用
WO2011156626A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
JP2020515604A (ja) 2017-03-29 2020-05-28 メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ 金属錯体
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
WO2019158453A1 (de) 2018-02-13 2019-08-22 Merck Patent Gmbh Metallkomplexe

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CHURRUCA, F. et al.，Direct, Two-Step Synthetic Pathway to Novel Dibenzo[a,c]phenanthridines，J. Org. Chem.，2005年，DOI:10.1021/jo0501036
FITZGERALD, J. J. et al.，Reaction of benzocyclobutene oxides with nitriles: synthesis of hypecumine and other 3-substituted isoquinolines，Tetrahedron Letters，1994年，Vol.35, No.49，DOI:10.1016/0040-4039(94)88462-5，pp.9191-9194
HUANG, Q. et al.，Synthesis of Substituted Isoquinolines by Electrophilic Cyclization of Iminoalkynes，Journal of Organic Chemistry，2002年，Vol.67, No.10，pp.3437-3444，DOI：10.1021/jo020020e
HUI, W. and DAI, Y.，Therapeutic potential of aryl hydrocarbon receptor ligands derived from natural products in rheumatoid arthritis，Basic Clin Pharmacol Toxicol.，2020年，Vol.126，pp.469-474，DOI:10.1111/bcpt.13372
KHADKA, D. B. et al.，Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors，European Journal of Medicinal Chemistry，2018年，Vol.143，pp.200-215，DOI:10.1016/j.ejmech.2017.11.011
KHADKA, D. B. et al.，Modification of 3-arylisoquinolines into 3,4-diarylisoquinolines and assessment of their cytotoxicity and topoisomerase inhibition，European Journal of Medicinal Chemistry，Vol.92，pp.583e607，DOI:10.1016/j.ejmech.2015.01.016
KIM, A. N. et al.，Iridium-Catalyzed Enantioselective and Diastereoselective Hydrogenation of 1,3-Disubstituted Isoquinolines，ACS Catalysis，2020年，Vol.10, No.5，pp.3241-3248, SI1-23，DOI:10.1021/acscatal.0c00211
MISHRA, P. K. et al.，Harnessing the reactivity of ortho-formyl-arylketones: base-promoted regiospecific synthesis of functionalized isoquinolines，Chemical Communications (Cambridge, United Kingdom)，2019年，Vol.55, No.57，pp.8278-8281，DOI ：10.1039/c9cc03689j
SMITH, S. H. et al.，Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans，Journal of Investigative Dermatology，2017年，Vol.137, No.10，pp.2110-2119，DOI:10.1016/j.jid.2017.05.004
SMUTNY, T. et al.，2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists，Journal of Medicinal Chemistry，2016年，Vol.59, No.10，pp.4601-4610，DOI:10.1021/acs.jmedchem.5b01891
STEJSKALOVA, L. et al.，Endogenous and Exogenous Ligands of Aryl Hydrocarbon Receptor: Current State of Art，Current Drug Metabolism，2011年，Vol.12，pp.198-212
TIWARI, V. K. et al.，One substrate, two modes of C-H functionalization: a metal-controlled site-selectivity switch in C-H arylation reactions，Organic Letters，2017年，Vol.19, No.1，pp.262-265，DOI:10.1021/acs.orglett.6b03558
YANG, S. H. et al.，Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents，Bioorganic & Medicinal Chemistry Letters，2010年，Vol.20, No.17，pp.5277-5281，DOI:10.1016/j.bmcl.2010.06.132

Also Published As

Publication number Publication date
WO2022015423A1 (en) 2022-01-20
US20230124135A1 (en) 2023-04-20
US11267788B2 (en) 2022-03-08
EP4185566A4 (en) 2024-12-04
EP4185566A1 (en) 2023-05-31
US20240208910A1 (en) 2024-06-27
EP4786453A2 (en) 2026-08-05
IL299756A (en) 2023-03-01
US20250282730A1 (en) 2025-09-11
US20220153703A1 (en) 2022-05-19
AU2021308209A8 (en) 2023-04-13
US11827605B2 (en) 2023-11-28
US12252471B2 (en) 2025-03-18
US20220017468A1 (en) 2022-01-20
CN116157387A (zh) 2023-05-23
US11548853B2 (en) 2023-01-10
EP4185566B1 (en) 2026-06-24
CN116157387B (zh) 2026-06-09
CA3185793A1 (en) 2022-01-20
MX2023000263A (es) 2023-03-29
JP2023533855A (ja) 2023-08-04
AU2021308209A1 (en) 2023-02-09
KR20230041021A (ko) 2023-03-23

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260421

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260519

R150 Certificate of patent or registration of utility model

Ref document number: 7867482

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150